The Effect of XueZhiKang on Fatigue：Comparing With Simvastatin

Phase 4

Completed

• Conditions: Dyslipidemias
• Interventions: Drug: XueZhiKang; Drug: simvastatin

• Registration Number: NCT01686451
• Lead Sponsor: Wenzhou Medical University

Brief Summary

Both XueZhiKang and Statins are cholesterol-lowering medications that are often prescribed for individuals with high cholesterol and who are at risk for cardiovascular disease (CVD). Several studies, including one randomized, double-blind, placebo-controlled clinical trial, have suggested that the use of statins is more frequently associated with fatigue. And XueZhiKang may be not. The purpose of this study is to compare the effect of these two medications on fatigue in persons who are at moderate to low CVD risk based on the risk estimation system in ESC(European Society of Cardiology)/ESA(European Atherosclerosis Society) guidelines (2011) for the management of dyslipidemias.

Detailed Description

Individuals at risk for cardiovascular disease (CVD) are often prescribed statins, which are medications that reduce the amount of cholesterol in the blood. By lowering cholesterol levels, these individuals have a lower incidence of coronary artery disease, ischemic stroke, and peripheral arterial disease and so on. While statins are effective at lowering cholesterol levels, their effect on fatigue is obvious and has been suggested by several studies, including one randomized, double-blind, placebo-controlled clinical trial. And XueZhiKang may be not. The purpose of this study is to compare the effect of these two medications on fatigue in persons who are at moderate to low CVD risk based on the risk estimation system in ESC(European Society of Cardiology)/ESA(European Atherosclerosis Society) guidelines (2011) for the management of dyslipidemias.

This study will enroll individuals who do not currently take cholesterol-lowering medications. Participants will be randomly assigned to receive 600mg of XueZhiKang twice a day, or 20mg of simvastatin daily for 4 weeks. Study visits will occur at baseline and Week 4. Blood will be collected for laboratory testing, and standardized psychological questionnaires will assess fatigue scores and physical activity levels at baseline and week 4. Pill count will be used to assess adherence of XueZhiKang and simvastatin treatment at week 4. At week 4, medication side effects will be monitored and tests of alanine aminotransferase (ALT), aspartate aminotransaminase (AST) and creatine phosphate kinase (CPK) will be performed. At week 4, medication efficacy will be assessed and test of low-density lipoprotein cholesterol (LDL-C) will be performed.

Study Timeline

• Study Start: 2012-08
• Study First Submitted: 2012-09-03
• Study First Submitted QC: 2012-09-12
• Study First Posted: 2012-09-18
• Primary Completion: 2013-09
• Study Completion: 2013-09
• Results First Submitted: 2013-10-08
• Status Verified: 2014-04
• Results First Submitted QC: 2014-04-20
• Last Update Submitted: 2014-04-20
• Results First Posted: 2014-05-19
• Last Update Posted: 2014-05-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. LDL cholesterol level between 115-190 mg/dL;
2. Able to fast prior to blood draw;
3. Able to comfortably read and write in Chinese;
4. Able and willing to refrain from donating whole blood during study participation;
5. Willing to abstain from consuming large amounts of grapefruit juice.

Exclusion Criteria

1. Current use of lipid-lowering medications;
2. Documented cardiovascular disease (CVD) by invasive or non-invasive testing (such as coronary angiography, nuclear imaging, stress echocardiography, carotid plaque on ultrasound), previous myocardial infarction (MI), acute coronary syndrome (ACS), coronary revascularization [percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG)] and other arterial revascularization procedures, ischaemic stroke, peripheral arterial disease(PAD);
3. Patients with type 2 diabetes, patients with type 1 diabetes with target organ damage (such as microalbuminuria);
4. Patients with moderate to severe chronic kidney disease [glomerular filtration rate (GFR) < 60 mL/min/1.73㎡];
5. Markedly elevated single risk factors such as familial dyslipidaemias and severe hypertension;
6. A calculated SCORE ≥5% for 10 year risk of fatal CVD;
7. Cancer;
8. HIV infected;
9. Medical or psychiatric condition that prevents full study participation or follow-up (e.g., active psychosis);
10. Active liver disease or unexplained persistent elevated transaminase levels；
11. Major surgery or hospitalization in the 3 months prior to study entry;
12. Current use of cyclosporin, erythromycin, clarithromycin, nefazodone, or any "azole" antifungals, including fluconazole, itraconazole, ketoconazole, mibefradil, or protease inhibitors;
13. Female of childbearing potential;
14. Current participation in another clinical trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
XueZhiKang	XueZhiKang	Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
Simvastatin	simvastatin	Participants will receive 20mg of simvastatin daily for 4 weeks.

Primary Outcome Measures

Name	Time	Method
Comparison Between XueZhiKang and Simvastatin on Fatigue Scores	Measured at baseline and week 4	At baseline and week 4, the fatigue score was assessed by a fatigue questionnaire named as Fatigue Assessment Scale (FAS) which used 10-item fatigue measure with the fatigue score ranged from 10-50. The higher score was meaning of higher level of fatigue.

Secondary Outcome Measures

Name	Time	Method
Treatment Efficacy	Measured at baseline and week 4	Treatment efficacy was estimated on the basis of triglyceride (TG), total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C), as well as LDL-C levels obtained at baseline and week 4.

Trial Locations

Locations (1)

Second Hispital of Wenzhou Medical University; 🇨🇳 Wenzhou, Zhejiang, China